Physician profile
Mark Xavier Ransom
NPI 1487686598
$555.88
in general payments reported to CMS, 2019-2025
12 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.53 · 2020: $11.67 · 2021: $28.15 · 2022: $44.17 · 2023: $96.44 · 2024: $205 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $115.63 | 2024-2025 | General - Female Sui, Axonics, Advantage System |
| Abbvie INC. | $90.77 | 2021-2025 | |
| Intuitive Surgical, INC. | $72.96 | 2023 | Da Vinci Surgical System |
| Axonics, INC. | $59.52 | 2023-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $45.48 | 2022-2025 | Veozah |
| Medtronic, INC. | $43.83 | 2024 | Interstim |
| Sumitomo Pharma America, INC. | $38.83 | 2024 | Gemtesa |
| Pfizer INC. | $24.53 | 2019 | |
| Urovant Sciences INC | $23.73 | 2022 | |
| Laborie Medical Technologies Corp. | $14.52 | 2024 | Endosheath Technology |
| Biogen, INC. | $14.41 | 2021 | |
| Olympus America INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ransom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.